Infliximab is an IgG 1 chimeric monoclonal antibody directed against tumor necrosis factor (TNF)-␣. 12 Two trials, Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, demonstrated that infliximab is effective for induction and maintenance of clinical response and remission in outpatients with moderately to severely active ulcerative colitis despite concurrent medications. 13 At the time of the publication of the ACT-1 and -2 studies, 13 colectomy outcomes were unknown for many of the patients; therefore, colectomy analysis was deferred. Subsequently, protocol amendments, study extensions, and targeted poststudy follow-up allowed more complete data collection for those whose colectomy status was unknown; a prespecified statistical analysis plan then enabled us to evaluate the effect of infliximab therapy on colectomy outcomes.
Materials and Methods

Patients, Design of the Studies, and Sources of Data
ACT-1 and -2 were randomized, double-blind, placebo-controlled trials conducted at 117 sites between March 2002 and March 2005. Patients were outpatients with moderately to severely active ulcerative colitis defined as a Mayo Clinic score 14 of 6 to 12 points and an endoscopic subscore of at least 2 points despite concurrent treatment with corticosteroids and/or azathioprine or 6-mercaptopurine and/or 5-aminosalicylate-containing medications (ACT-2 only). Patients who received intravenous corticosteroids within 2 weeks or were judged likely to require colectomy within 12 weeks were excluded. Standard chest radiographs were obtained during screening. Patients with positive tuberculin skin tests with the use of purified protein derivative were ineligible. 13 Eligible patients had an established diagnosis of ulcerative colitis. Endoscopy with biopsy was performed during screening to confirm the diagnosis of ulcerative colitis by both the physician performing the endoscopy and the pathologist reviewing the biopsy specimen. Patients with a diagnosis of indeterminate colitis, Crohn's disease, or clinical findings suggestive of Crohn's disease (ie, fistula or granuloma on biopsy) were ineligible. 13 Patients were randomized to receive intravenous infliximab (REMICADE®; Centocor Ortho Biotech, Inc, Malvern, PA) at doses of 5 or 10 mg/kg or placebo at weeks 0, 2, and 6 and then every 8 weeks through week 46 (ACT-1) or 22 (ACT-2). At week 30, patients who completed ACT-2 and in the opinion of the investigator would benefit from continued treatment were eligible to continue the same blinded treatment in a study extension. Patients were followed through 54 weeks. The primary efficacy end point in both trials was clinical response at week 8, 13 and the incidence of colectomy was a secondary efficacy end point specified in each protocol.
Patients who discontinued ACT-1 or -2 (including the extension) prior to 54 weeks were eligible to enter REMICADE Safety Under Long-term Study in Ulcerative Colitis (RESULTS-UC), a safety follow-up study (Figure 1 ). Data were obtained on colectomy, hospitalization, commercial infliximab use, death, serious infection, new malignancy, autoimmune diseases, and delayed hypersensitivity reactions. In response to a lower than expected participation rate in RESULTS-UC and to optimize colectomy follow-up through 54 weeks after the first infusion, the ACT-1 and -2 protocols were amended in January 2006 to include a targeted poststudy follow-up, in which data through 54 weeks on colectomy, hospitalization, and commercial infliximab use were retrospectively collected in patients who discontinued treatment and did not enter RESULTS-UC ( Figure 1 ). Data through 54 weeks from all data sources were pooled and analyzed according to the prespecified plan.
The Institutional Review Board at each site approved all protocols and amendments. All patients gave written informed consent for study procedures, and additional informed consent was sought for patients targeted for poststudy follow-up.
Efficacy Evaluations
Data for patients were evaluated through 54 weeks or last follow-up visit for colectomy with the time to colectomy as the primary end point in this prespecified combined analysis. Data were also analyzed for ulcerative colitis-related hospitalizations and surgeries/procedures (all surgeries and endoscopic procedures used to evaluate or treat ulcerative colitis) and colectomy.
Safety Evaluations
Adverse events through 54 weeks were summarized. Sera for determination of antibodies to infliximab, antinuclear antibodies, and anti-double-stranded DNA antibodies were collected at weeks 0, 30, and 54 and analyzed as previously described. 13, 15 
Statistical Analysis
The primary end point was time to colectomy through 54 weeks after the first infusion in patients enrolled in the combined ACT-1 and -2 trials. Time to colectomy for patients who did not have a colectomy was censored at the last follow-up date through 54 weeks. Time to colectomy was summarized as the cumulative incidence of colectomy through 54 weeks estimated by the Kaplan-Meier product-limit method; the placebo and the combined infliximab groups were compared using the log-rank test stratified by study.
Other secondary end points were the numbers of ulcerative colitis-related hospitalizations and surgeries/procedures through 54 weeks. The numbers of ulcerative colitis-related hospitalizations and surgeries/procedures through 54 weeks were expressed as events per 100 patient-years, and the combined infliximab and placebo groups were compared using the Wilcoxon rank-sum test.
To evaluate the consistency of treatment effect between infliximab and placebo, prespecified subgroup analyses included the following: study (ACT-1 or ACT-2), treatment group (infliximab 5 or 10 mg/kg groups), and 16 demographic or baseline disease characteristics ( Figure 2B ). The hazard ratio, 95% confidence intervals, and interaction P values were calculated based on Cox proportional hazards model stratified by study (if applicable).
Analyses to identify predictors of colectomy from a pool of baseline demographic and disease characteristics and treatment were performed post hoc using Cox proportional hazards models. Demographic and baseline characteristics were compared using a 2 or Fisher exact test for categorical variables or t test for continuous variables. Safety analyses used the Fisher exact test to compare placebo and the combined infliximab group.
The sample sizes for ACT-1 and -2 were based on the primary end point of clinical response at week 8. To increase the power to detect a treatment difference for the colectomy end point, the 2 studies and the 2 infliximab groups were pooled. Assuming a hazard ratio of 0.5, and a 2-sided significance level of .05, at least 74 events would provide 80% power to detect a significant difference in the time to colectomy between the combined infliximab and placebo groups. All efficacy analyses used intention-to-treat methods. All reported P values are 2-sided and not adjusted for multiple testing.
Results
Patient Disposition and Baseline Characteristics
In the ACT-1 and -2 trials, 728 patients were randomized to treatment: 244 to placebo and 242 each to infliximab 5 and 10 mg/kg. The baseline characteristics were generally similar among treatment groups (Table 1) . One hundred forty-two patients from ACT-2 entered the extension trial (31 in the placebo group, and 52 and 59 in the infliximab 5-and 10-mg/kg groups, respectively), 284 patients from ACT-1 and -2 entered RESULTS-UC, and 135 patients with incomplete colectomy data through 54 weeks were targeted for poststudy follow-up, of whom only 37 patients gave consent for colectomy data collection ( Figure 1) .
Pooling all data sources, 630 of 728 randomized patients (87%) had complete colectomy follow-up data through 54 weeks: (1) 55.1% (401 of 728) of patients from ACT-1 or ACT-2 through extension week 24; (2) 26.4% (192 of 728) of patients from RESULTS-UC; and (3) 5.1% (37 of 728) of patients through targeted poststudy fol-low-up ( Figure 1) . The remaining 98 patients (13%) (Figure 1) had a median follow-up of 6.2 months (range, 0.5-11.7 months). When measured by the total patientyears of follow-up, 91.6% of potential colectomy follow-up (646.4 patient-years of 705.6 potential patientyears; Table 2 ) was obtained. Overall, more patients had complete colectomy follow-up in the infliximab groups as compared with placebo.
Among 98 patients with incomplete colectomy follow-up (42 in the placebo group, and 24 and 32 in the infliximab 5-and 10-mg/kg groups, respectively), informed consent could not be obtained because 53 were lost to follow-up, 33 were at sites that did not participate in the targeted poststudy follow-up data collection, 11 refused to consent, and 1 patient withdrew consent. These patients had a median follow-up of 6.2 months.
Treatment was discontinued prematurely by 54% (132 of 244) of patients in the placebo group and by 30% (72 of 242) and 32% (78 of 242) of patients in the infliximab 5-and 10-mg/kg groups, respectively (P Ͻ .001 for all comparisons with placebo). 
Efficacy
Time to colectomy through 54 weeks. Eighty-two patients (36 who received placebo; 28 and 18 who received infliximab 5 and 10 mg/kg, respectively) had a colectomy through 54 weeks. The determination of whether or not to proceed to colectomy was based on medical judgment; no criteria were prespecified to determine whether a patient should proceed to colectomy. The reason for colectomy was found to be exacerbation of disease or failure of medical management in 82% (67 of 82) of patients. More than 95% (79 of 82) of patients with colectomies had active ulcerative colitis based on historical, surgical, and/or pathologic evidence. Based on available data for the Mayo score before colectomy, 11% (9 of 82) of patients did not have moderately or severely active ulcerative colitis and had other medical reasons for colectomy (eg, reluctance to remain on corticosteroid therapy, pathology results indicative of active disease).
The cumulative incidence of colectomy through 54 weeks was greater for the placebo group (17%) than for the combined infliximab group (10%) (P ϭ .02; Figure 2A ; Table 2 ), yielding an absolute risk reduction of 7% with a 95% confidence interval of (0.01-0.12). The hazard ratio of 0.59 represents a 41% reduction in the risk of colectomy for the combined infliximab group compared with the placebo group ( Figure 2B ).
Patients who received either dose of infliximab had a lower risk of undergoing colectomy than those treated with placebo, but the difference was only significant for 10 mg/kg (P ϭ .007) (Table 2, Figure 2B ). There appears to be a difference in the treatment effect of infliximab between studies (interaction, P ϭ .09), where the overall treatment effect was mainly driven by the difference observed in ACT-2. Efficacy of infliximab was generally consistent among demographic and baseline disease characteristics ( Figure 2B) .
In a multivariate Cox proportional hazards model, in addition to treatment with placebo, concomitant corticosteroid use, baseline C-reactive protein concentrations of at least 2 mg/dL, North American center location, disease duration less than 3 years, and a baseline Mayo score of at least 10 points were significantly associated with the risk of colectomy. Results of the full Cox proportional hazards model are presented in Table 3 . Secondary end points. There was a significantly reduced number of ulcerative colitis-related hospitalizations per 100 patient-years of treatment for the 5-mg/kg (21), 10-mg/kg (19) , and combined (20) infliximab groups compared with placebo (40; P ϭ .02, P ϭ .007, and P ϭ .003, respectively; Table 2 ).
There was a significantly reduced number of ulcerative colitis-related surgeries/procedures per 100 patient-years of treatment for the infliximab 10 mg/kg (19) and combined infliximab (21) groups compared with placebo (34; P ϭ .02, P ϭ .03, respectively; Table 2 ). The number of ulcerative colitis-related surgeries/procedures in patients who received infliximab 5 mg/kg was 22 compared with 34 in patients who received placebo (P ϭ .15).
Commercial infliximab was used by 11% (27 of 244) of patients in the placebo group compared with 6% (28 of 484) in the combined infliximab group. Based on this observation, "rescue" therapy with commercial infliximab after study discontinuation was evaluated as a potential confounder to the colectomy analysis ( Figure 2C ). Post hoc analyses of the time to colectomy or use of commercial infliximab demonstrated that infliximab 5 and 10 mg/kg significantly reduced the incidence of colectomy or commercial infliximab use compared with placebo (P ϭ .001 and P Ͻ .001, respectively). These results are consistent across dose groups and studies.
Safety
The cumulative safety experience through 54 weeks includes data collected from all sources (Table 4) . Among all patients, the mean duration of treatment was 23 weeks in the placebo group as compared with 33 weeks in the combined infliximab group (Table 4) . The proportion of patients with adverse events was slightly lower in the placebo group (80%) compared with the combined infliximab group (86%) ( Table 4) . Treatment was discontinued because of an adverse event in 9% of patients in the placebo group compared with 7% in the combined infliximab group. Serious adverse events occurred in 23% of patients in the placebo group and 18% of patients in the combined infliximab group. Infections occurred in 40% in the combined infliximab group compared with 33% in the placebo group (Table 4) . Serious infections occurred in 4% in the combined infliximab group and 2% in the placebo group. One patient each who received infliximab developed tuberculosis and histoplasmosis. Herpes zoster and varicella zoster occurred in 1% and 0.4%, respectively, in the combined infliximab group, and 0.4% for both in the placebo group.
As reported previously, 4 patients developed cancer 13 : 2 (prostate adenocarcinoma, rectal adenocarcinoma) and 1 (basal cell carcinoma) in patients who received infliximab 5 mg/kg and 10 mg/kg, respectively, and 1 who received placebo (basal cell carcinoma). Through 54 weeks in RESULTS-UC, 1 new cancer (squamous cell skin carcinoma) developed in a patient who received infliximab 5 mg/kg. Additionally, 1 patient in each of the 3 treatment groups developed colonic dysplasia through 54 weeks, including 1 reported previously. 13 Through 54 weeks, new autoimmune disorders occurred in 2 patients who received infliximab (lupus-like reaction and sicca syndrome) and 1 patient who received placebo (rheumatoid arthritis). As reported previously, 2 patients reported optic neuritis and 1 patient reported a multifocal motor neuropathy with conduction block syndrome; all 3 patients received infliximab. 13 Through 54 weeks, no new adverse events of neuropathy were reported.
No patients died through 54 weeks. After 54 weeks, 6 patients died, 4 who received infliximab (histoplasmosis 4 weeks after the last infusion, 13 listeria encephalitis 3 years after the last infusion, prostate cancer 3.5 years after the last infusion, and natural causes 10 months after the last infusion) and 2 who received placebo (suicide and cerebrovascular accident).
Discussion
There has been a paucity of data published on colectomy outcomes in patients with ulcerative colitis who are treated with biologic therapy. Prior to the pub- 31 (13) 22 (9) 36 (15) 58 (12) Nausea 23 (9) 21 (9) 32 (13) 53 (11) Upper respiratory tract infection 43 (18) 39 (16) 48 (20) 87 (18) Pharyngitis 16 (7) 23 (10) 27 (11) 50 (10) Sinusitis 12 (5) 20 (8) 25 (10) 45 ( 30 (12) 25 (10) 29 (12) 54 (11) Fatigue 19 (8) 21 (9) 29 (12) 50 (10) Arthralgia 26 (11) 40 (17) 32 (13) 72 (15) Fever 22 (9) 27 (11) 23 (10) 50 (10) Headache 45 (18) 44 (18) 46 (19) 90 (19) Anemia 25 (10) 11 (5) 14 (6) 25 ( 23 (9) 14 (6) 20 (8) 34 (7) .31 Serious adverse events, n (%) 57 (23) 43 (18) 46 (19) 89 (18) .12 Infections, n (%)
80 (33) 94 (39) 100 (41) 194 (40) .06 Serious infections, n (%)
6 (2) 7 (3) 12 (5) 19 (4) .39 
lication of the ACT trial results, 2 placebo-controlled pilot studies suggested that infliximab might reduce short-term colectomy rates in hospitalized patients with corticosteroid-refractory ulcerative colitis: in 1 study, 3 of 3 patients in the placebo group and 4 of 8 patients in the infliximab group underwent colectomy during shortterm follow-up; 10 in a second study, 14 of 21 patients in the placebo group and 7 of 24 patients in the infliximab group underwent colectomy by week 12. 11 To evaluate the role of anti-TNF-␣ therapy in preventing colectomy, a prespecified analysis was planned, and a comprehensive program was developed to obtain colectomy outcome data from the large cohort of 728 patients in the ACT trials.
In the ACT trials, treatment with infliximab was associated with an absolute risk reduction of 7% in the incidence of colectomy through 54 weeks in outpatients with moderately to severely active ulcerative colitis despite concurrent medications. Of note, patients who received either dose of infliximab had a lower risk of undergoing colectomy than those treated with placebo (36 of 244 patients, 17%); this difference was significant in the 10-mg/kg group (18 of 242 patients, 8%; P ϭ .007) but not in the 5-mg/kg group (28 of 242 patients, 12%; P ϭ .166).
A low colectomy rate was expected in the ACT trials (eligible patients were outpatients who had not received intravenous corticosteroids within 2 weeks and were judged unlikely to require colectomy within 12 weeks). Thus, the overall treatment effect of infliximab associated with an absolute risk reduction for colectomy of 7% needs to be considered in the context of this clinical outcome, which occurs infrequently.
Whereas the colectomy rate in patients with moderateto-severe ulcerative colitis was reduced with infliximab therapy in this study, more evidence-based use of infliximab is needed to evaluate the short-and long-term clinical outcomes. Recently, a long-term, retrospective review of colectomy rates in 314 patients with acute severe ulcerative colitis showed that urgent colectomy was avoided in steroid-refractory patients, but the longterm risk of elective colectomy was not reduced. 16 The results of a small, single-center, retrospective uncontrolled analysis of 15 ulcerative colitis patients who received a single infusion of infliximab 5 mg/kg showed that infliximab prevented colectomy in patients with more acute disease (ie, those receiving azathioprine/6-mercaptopurine for less than 8 weeks) compared with those receiving long-term maintenance immunomodulators. 17 Our results show that induction followed by maintenance therapy with infliximab reduced the rate of colectomy through week 54, which may or may not have been elective, and duration of disease (Յ5 years vs Ͼ5 to Յ15 years vs Ͼ15 years) did not have a significant impact on colectomy rates. Also, previous analyses showed that duration of disease did not affect rates of clinical response, clinical remission, or mucosal healing (Ͻ3 years vs Ն3 years). 18 Hospitalization accounts for approximately 50% of all lifetime costs associated with ulcerative colitis. 19 -23 The NOTE. The composite of ACT 1 through week 54, ACT 2 through week 30, and safety data collected and verified from the ACT 2 study extension through week 24 are summarized in this Table. In addition, safety data are also included from RESULTS-UC and poststudy safety experience through 54 weeks after the first study medication infusion in ACT 1 or ACT 2 and are summarized for infliximab, irrespective of dose group, and placebo. Em dashes denote not applicable. Safety data through week 54 of ACT 1 and week 30 of ACT 2 have been reported previously 13 but are also included here to represent the complete safety experience from these studies. rates of hospitalization for ulcerative colitis in population-based studies in Canada and the United States range from 8 to 13 per 100,000 individuals. [23] [24] [25] In the ACT trials, infliximab reduced the rates of ulcerative colitisrelated hospitalizations (40 vs 20, respectively) and surgeries/procedures (34 vs 21, respectively) per 100 patientyears of treatment in outpatients with moderately to severely active ulcerative colitis. Pharmacoeconomic and health utility studies are needed to understand better the costs and overall outcomes of infliximab in the management of ulcerative colitis. The adverse events observed through 54 weeks in the ACT trials are comparable with those reported with other indications for infliximab. 26 Pneumonia occurred with greater frequency with infliximab compared with placebo. In our safety analysis through 54 weeks, serious adverse events occurred in 23% of patients in the placebo group and 18% of patients in the combined infliximab group. Review of data available from serious adverse event reports indicates no notable complications in patients undergoing colectomy, and no pattern was observed between treatment groups.
Anti-TNF-␣ therapies including infliximab have been associated with the potential to increase the risk for infection (some fatal) including sepsis, pneumonia, reactivation of latent tuberculosis, histoplasmosis, and other opportunistic infections; neurologic events (eg, new onset or exacerbation of demyelinating disease); autoimmune disease; and hepatitis B reactivation. There is a possible association for increased risk for malignancy with anti-TNF-␣ therapies, including lymphoma (including recent reports of hepatosplenic T-cell lymphoma), lung cancer, and other malignancies; however, long-term follow-up is needed to characterize better this risk. 26, 27 Taken together, the occurrence of herpes zoster, pulmonary tuberculosis, fatal histoplasmosis, and listeriosis, and malignancies seen in patients treated with infliximab in ACT-1 and ACT-2 highlights the importance of vigilance for opportunistic infections and other adverse events possibly related to immunosuppressive therapy. 28 Studies of longer duration are needed to assess better the risk-benefit profile of infliximab in patients with ulcerative colitis.
Several limitations of this study warrant mention. Whereas significant improvement in colectomy rate for patients receiving the 10-mg/kg dose of infliximab as opposed to the lower dose and placebo was observed, it is not possible to make a definitive conclusion regarding the dose of infliximab that would have a better colectomysparing effect because the differences observed could have resulted from factors including the low incidence of colectomy within each dose analysis and the differential use of commercial infliximab. The prespecified primary analysis that pooled study populations and combined infliximab dose groups provided the best estimate of the treatment effect of infliximab in reducing the incidence of colectomy. Overall, the greater use of commercial infliximab by patients in the placebo group (27 of 244 patients, 11%) compared with that in the combined infliximab group (28 of 484 patients, 6%) was a potential confounding factor in the original analyses necessitating the exploratory analyses of time to colectomy or use of commercial infliximab. Our study is also limited by the colectomy follow-up differential between the placebo and infliximab groups and the overall proportion of patients with incomplete colectomy follow-up (13%) because informed consent could not be obtained to collect colectomy follow-up data. A general 5-and-20 rule for loss of follow-up in clinical trials suggests that a 5% loss probably leads to little bias and that greater than 20% loss potentially compromises the validity of a trial. Although our study falls within these limits, the expectation for loss of follow-up may trend high because of the length of follow-up (54 weeks) and low expected outcome event rate for colectomy. 29 In conclusion, treatment with infliximab at weeks 0, 2, and 6 and then every 8 weeks reduced the incidence of colectomy through 54 weeks by 41% in outpatients with moderately to severely active ulcerative colitis despite concurrent medications.
